International Society of Geriatric Oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patients.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  European Journal of Cancer

• Publication date

  2007-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.EJCA.2006.12.006PMID 17258449
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Bisphosphonates for malignancy-related bone disease: current status, future developments

  2006influential reference
• Epidemiology of pain

  2006cited by this paper
• Systematic Review: Bisphosphonates and Osteonecrosis of the Jaws

  2006cited by this paper
• Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer.

  2006cited by this paper
• Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws.

  2006cited by this paper
• Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper.

  2005cited by this paper
• Effect of oral ibandronate versus intravenous (i.v.) zoledronic acid on markers of bone resorption in patients with breast cancer and bone metastases: Results from a comparative phase III trial

  2005cited by this paper
• Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid.

  2005cited by this paper
• Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration

  2005cited by this paper
• Bisphosphonate‐associated osteonecrosis of mandibular and maxillary bone

  2005cited by this paper
• Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.

  2005cited by this paper
• Hypodermoclysis: An Alternate Method for Rehydration in Long‐term Care

  2005cited by this paper
• Bisphosphonate safety and tolerability.

  2005influential reference
• Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.

  2005cited by this paper
• Hypercalcemia of malignancy.

  2004cited by this paper
• Toward new horizons: the future of bisphosphonate therapy.

  2004cited by this paper
• Safety of Long-Term Administration of Bisphosphonates in Elderly Cancer Patients

  2004cited by this paper
• Renal dysfunction associated with bisphosphonate use: Retrospective analysis of 293 patients with respect to age and other clinical characteristics.

  2004cited by this paper
• Capecitabine (X) monotherapy in patients (pts) with pretreated metastatic breast cancer (MBC): Is response correlated to cerbB-2 expression?

  2004cited by this paper
• Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy.

  2004cited by this paper
• Zoledronic acid (Z) as palliative treatment in cancer patients with bone metastases: Interim results of a prospective, open-label trial.

  2004cited by this paper
• Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion

  2004cited by this paper
• Bone resorption predicts for skeletal complications in metastatic bone disease

  2003cited by this paper
• Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer.

  2003cited by this paper
• American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer.

  2003influential reference
• Extended Safety Profile of Oral Clodronate After Long-Term Use in Primary Breast Cancer Patients

  2003cited by this paper
• Toxic acute tubular necrosis following treatment with zoledronate (Zometa).

  2003cited by this paper
• American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma.

  2002cited by this paper
• Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease.

  2001cited by this paper
• Long‐term follow‐up of a prospective, double‐blind, placebo‐controlled randomized trial of clodronate in multiple myeloma

  2001cited by this paper
• Multiple myeloma and renal failure.

  2000cited by this paper
• 8 Pain in Older People

  1999cited by this paper
• Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group.

  1999cited by this paper
• A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma

  1998cited by this paper
• Markers of bone resorption in patients treated with pamidronate.

  1998cited by this paper
• Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group.

  1998cited by this paper
• Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease.

  1997cited by this paper
• Metabolic effects of pamidronate in patients with metastatic bone disease.

  1996cited by this paper
• Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group.

  1996cited by this paper
• Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group.

  1996cited by this paper
• Effect of oral clodronate on metastatic bone pain: a double-blind, placebo-controlled study.

  1995cited by this paper
• Markers of bone resorption in patients treated with pamidronate

  1995cited by this paper
• Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer.

  1993cited by this paper
• Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group.

  1992cited by this paper
• Renal toxicities of chemotherapy.

  1992cited by this paper
• Breast cancer (2).

  1992cited by this paper
• Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma

  1992cited by this paper
• Is there such a thing as geriatric pain?

  1991cited by this paper
• Breast Cancer 4

  1981cited by this paper

• Cancer and ageing

  2022cites this paper
• Bone Health and Cancer Therapy

  2022cites this paper
• Oncological emergencies

  2022cites this paper
• Prevention and Treatment of Skeletal Complications

  2019cites this paper
• Hypercalcemia: Other Causes than Primary Hyperparathyroidism

  2019cites this paper
• SIOG guidelines- essential for good clinical practice in geriatric oncology.

  2019cites this paper
• Efficacy and safety of de-escalation bone- modifying agents for cancer patients with bone metastases: a systematic review and meta-analysis

  2018cites this paper
• Toxicity of Cancer Therapies in Older Patients

  2018cites this paper
• Long-term oral bisphosphonates delay healing after tooth extraction: a single institutional prospective study

  2018cites this paper
• Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

  2017cites this paper
• Important side effect of zoledronic acid treatment in metastatic breast cancer: renal failure

  2016cites this paper
• A Case of Severe, Prolonged, Refractory Hypophosphatemia After Zoledronic Acid Administration

  2016cites this paper
• Bone health in the elderly cancer patient: A SIOG position paper.

  2016cites this paper
• [Professional's expectations to improve quality of care and social services utilization in geriatric oncology].

  2015cites this paper
• Incidence of bisphosphonate-related osteonecrosis of the jaw in high-risk patients undergoing surgical tooth extraction.

  2015cites this paper
• Attentes des professionnels hospitaliers impliqués dans la prise en charge globale en oncogériatrie

  2015cites this paper
• Bone health in cancer patients: ESMO Clinical Practice Guidelines.

  2014cites this paper
• Prevalence of renal insufficiency in elderly cancer patients in a tertiary cancer center

  2014cites this paper
• Management of Metastatic Bone Disease in the Elderly with Bisphosphonates and RANKL Inhibitors: Effectiveness and Safety

  2014cites this paper
• Prevalência de insuficiência renal em pacientes idosos com câncer em um centro de tratamento oncológico Prevalence of renal insufficiency in elderly cancer patients in a tertiary cancer center

  2014cites this paper
• Non-malignant causes of hypercalcemia in cancer patients: a frequent and neglected occurrence

  2013cites this paper
• Cancer-associated bone disease

  2013cites this paper
• Bone-Targeted Therapies for Elderly Patients with Renal Cell Carcinoma: Current and Future Directions

  2013influential citation
• Management of metastatic bone disease in the elderly with bisphosphonates and receptor activator of NF-kB ligand inhibitors: effectiveness and safety.

  2013influential citation
• Clinical and organizational factors in the initial evaluation of patients with lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

  2013cites this paper
• Bone Health in Patients with Breast Cancer: Recommendations from an Evidence-Based Canadian Guideline

  2013cites this paper
• Importance of monitoring renal function in patients with cancer.

  2012cites this paper
• 108 Cancer and ageing

  2012cites this paper
• Antiresorptive therapies in oncology and their effects on cancer progression.

  2012cites this paper
• Efficacy and tolerability of medical ozone gas insufflations in patients with osteonecrosis of the jaw treated with bisphosphonates—Preliminary data

  2012cites this paper
• Cancer and ageing

  2012cites this paper
• The International Society of Geriatric Oncology conference: Paris 2011

  2012cites this paper
• The Italian cross-sectional survey of the management of bone metastasis: ZeTa study

  2012cites this paper
• Could targeting bone delay cancer progression? Potential mechanisms of action of bisphosphonates.

  2012cites this paper
• Perspectives in the elderly patient: benefits and limits of bisphosphonates and denosumab.

  2012cites this paper
• Antiresorptive treatment options and bone health in cancer patients-safety profiles and clinical considerations.

  2012cites this paper
• Malignant hypercalcemia.

  2011cites this paper
• Cancer in the elderly

  2011cites this paper
• Les soins de support en oncogériatrie: une aide pour les malades tout au long de la maladie

  2011cites this paper
• Efficacy and safety of medical ozone (O(3)) delivered in oil suspension applications for the treatment of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: Preliminary results of a phase I-II study.

  2011cites this paper
• Zoledronic-acid

  2011cites this paper
• Osteonecrosis of the jaw and bisphosphonates in cancer: a narrative review

  2011cites this paper
• Le cancer du sein de la femme âgée

  2011cites this paper
• Case histories: breast cancer

  2011cites this paper
• Supportive Care in Elderly Cancer Patients

  2010cites this paper
• Challenges in Clinical Patient Management

  2010cites this paper
• Assessing older prostate cancer patients for chemotherapy: recommendations from the International Society of Geriatric Oncology

  2010cites this paper
• Prevalence of renal insufficiency in breast cancer patients and related pharmacological issues

  2010cites this paper
• Bisphosphonate-Related Osteonecrosis of the Jaw: Tip of the Iceberg

  2010influential citation
• Geriatric Oncology: Introduction

  2009cites this paper
• Drug management of prostate cancer: prevalence and consequences of renal insufficiency.

  2009cites this paper
• Toxicity of Bisphosphonates

  2009cites this paper
• Management of primary and advanced breast cancer in older unfit patients (medical treatment).

  2009cites this paper
• Optimising care of elderly breast cancer patients: a challenging priority.

  2009cites this paper
• Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan.

  2009cites this paper
• Treatment of prostate cancer in unfit senior adult patients.

  2009cites this paper
• Preserving functional independence in elderly patients with cancer-associated bone disease: the role of zoledronic acid

  2009cites this paper
• Osteonecrosi mascellare da bifosfonati: lo stato dell'arte

  2009cites this paper
• Are bisphosphonates the suitable anticancer drugs for the elderly?

  2009cites this paper
• Cancer in older people: a tale of two disciplines

  2009cites this paper
• Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel.

  2008cites this paper
• Recomendaciones para la prevención de la osteonecrosis de los maxilares (ONM) en pacientes con cáncer tratados con bisfosfonatos intravenosos

  2008cites this paper
• Medical approach to advanced prostate cancer in older patients

  2008influential citation
• Managing neoplastic bone disease with ibandronic acid: a preclinical and clinical data update.

  2008cites this paper
• Drugs for hypercalcemia

  2008cites this paper
• Managing neoplastic bone disease with ibandronic acid: a preclinical and clinical data update

  2008cites this paper
• Pattern of intravenous bisphosphonate use in outpatient care in Germany

  2008cites this paper
• Oral osteonecrosis associated with the use of ibandronate: report of a case and clinical implications.

  2008cites this paper
• Frequency and Risk Factors Associated With Osteonecrosis of the Jaw in Cancer Patients Treated With Intravenous Bisphosphonates

  2008cites this paper
• Vulnerable and frail elderly: an approach to the management of the main tumour types.

  2008cites this paper
• Geriatric oncology: a field coming of age.

  2007cites this paper
• Bisphosphonate-related Osteonecrosis of the Jaws: An Update on Clinical, Pathological and Management Aspects

  2007cites this paper
• Bisphosphonate-related osteonecrosis of the jaw (BRONJ): run dental management designs and issues in diagnosis.

  2007cites this paper
• Pathophysiology, risk factors and management of bisphosphonate-associated osteonecrosis of the jaw: Is there a diverse relationship of amino- and non-aminobisphosphonates?

  2007cites this paper
• Comprendre le score gériatrique: recommandations de la « Task Force on CGA of the International Society of Geriatric Oncology (SIOG) »

  2007cites this paper
• Bisphosphonate - related osteonecrosis of the jaws: the point of view of the oral pathologist.

  2007cites this paper
• Biomedical Imaging and Intervention Journal Innovations in Chemotherapy and Radiation Therapy: Implications and Opportunities for the Asia-pacific Rim

  year unknowncites this paper